Edition:
United States

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.79USD
8 Dec 2017
Change (% chg)

$0.03 (+1.70%)
Prev Close
$1.76
Open
$1.77
Day's High
$1.84
Day's Low
$1.74
Volume
18,864
Avg. Vol
145,386
52-wk High
$5.50
52-wk Low
$1.08

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $41.32
Shares Outstanding(Mil.): 23.08
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

Nov 09 2017

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

Oct 04 2017

BRIEF-Catabasis Pharmaceuticals Q2 loss per share $0.32

* Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress

Aug 10 2017

Earnings vs. Estimates